Table 2. Baseline characteristics of participants enrolled by prior exposure to single-dose nevirapine in the NNRTI Response Study—Zambia, Kenya, Thailand (2005–2008).
| Characteristics | Unexposed to Single-Dose Nevirapine (N = 523) | Exposed to Single-Dose Nevirapine (N = 355) | Total | |||
| n (%) | Median (IQR) | n (%) | Median (IQR) | n (%) | Median (IQR) | |
| Age, y | 33 (29–39) | 29 (26–33)* | 32 (28–36) | |||
| <30 | 136 (26) | 182 (51) | 318 (36) | |||
| Weight, kg | 52 (47–58) | 51 (45–58) | 52 (46–58) | |||
| <50 | 200 (38) | 145 (41) | 345 (39) | |||
| Body mass index, kg/m2 | 20.2 (18.4–22.6) | 19.7 (18.0–22.3) | 20.0 (18.3–22.5) | |||
| <18 | 111 (21) | 89 (25) | 200 (23) | |||
| WHO stage | ||||||
| I or II | 236 (45) | 180 (51) | 416 (47) | |||
| III | 219 (42) | 139 (39) | 358 (41) | |||
| IV | 68 (13) | 36 (10) | 104 (12) | |||
| CD4+ lymphocyte count, cells/µl | 139 (71–209) | 160 (90–219)* | 147.5 (77–215) | |||
| 0 to 49 | 98 (19) | 46 (13) | 144 (16) | |||
| 50 to 199 | 280 (54) | 199 (56) | 479 (55) | |||
| ≥200 | 145 (28) | 110 (31) | 255 (29) | |||
| Plasma viral load, log copies/ml [missing = 6] | 5.2 (4.6–5.6) | 5.0 (4.3–5.4)* | 5.1 (4.5–5.5) | |||
| <4.0 | 52 (10) | 62 (17) | 114 (13) | |||
| 4.0 to <5.0 | 179 (34) | 117 (33) | 296 (34) | |||
| ≥5.0 | 288 (55) | 174 (49) | 462 (53) | |||
| Hemoglobin, g/dl (missing = 16) | 10.8 (9.5–12.0) | 11.0 (9.8–12.2) | 10.9 (9.6–12.1) | |||
| <8.0 | 31 (6) | 23 (7) | 54 (6) | |||
| NNRTI initially prescribed | ||||||
| NVP | 481 (91) | 339 (95) | 820 (93) | |||
| EFV | 42 (8) | 16 (5) | 58 (7) | |||
| TB at baseline | 53 (10) | 18 (5) | 71 (8) | |||
*p-Value<0.05, compared to unexposed by Wilcoxon rank-sum test.